S
Suzanne F. Jones
Researcher at Sarah Cannon Research Institute
Publications - 204
Citations - 7935
Suzanne F. Jones is an academic researcher from Sarah Cannon Research Institute. The author has contributed to research in topics: Cancer & Tolerability. The author has an hindex of 42, co-authored 194 publications receiving 7064 citations. Previous affiliations of Suzanne F. Jones include University of North Carolina at Chapel Hill & Seattle Children's Research Institute.
Papers
More filters
Journal ArticleDOI
Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
Howard A. Burris,Herbert Hurwitz,E. Claire Dees,Afshin Dowlati,Kimberly L. Blackwell,Bert H. O'Neil,Paul K. Marcom,Matthew J. Ellis,Beth Overmoyer,Suzanne F. Jones,Jennifer Harris,Deborah A. Smith,Kevin M. Koch,Andrew G. Stead,Steve Mangum,Neil L. Spector +15 more
TL;DR: Lapatinib was well tolerated at doses ranging from 500 to 1,600 mg once daily and clinical activity was observed in heavily pretreated patients with ErbB1-expressing and/or ErbbB2-overexpressing metastatic cancers, including four PRs in patients with trastuzumab-resistant breast cancers and prolonged stable disease in 10 patients.
Journal ArticleDOI
Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
Ian E. Krop,Muralidhar Beeram,Shanu Modi,Suzanne F. Jones,S. N. Holden,Wei Yu,Sandhya Girish,Jay Tibbitts,Joo-Hee Yi,Mark X. Sliwkowski,Fred Jacobson,Stuart G. Lutzker,Howard A. Burris +12 more
TL;DR: At the MTD of 3.6 mg/kg every 3 weeks, T-DM1 was associated with mild, reversible toxicity and substantial clinical activity in a heavily pretreated population of patients with advanced HER2-positive breast cancer.
Journal ArticleDOI
Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
Josep Tabernero,Federico Rojo,Emiliano Calvo,Howard A. Burris,Ian Judson,Katharine Hazell,Erika Martinelli,Santiago Ramón y Cajal,Suzanne F. Jones,Laura Vidal,N. Shand,Teresa Macarulla,Francisco Javier Ramos,Sasa Dimitrijevic,Ulrike Zoellner,Pui Tang,Michael Stumm,Heidi Lane,David Lebwohl,José Baselga +19 more
TL;DR: Everolimus achieved mTOR signaling inhibition at doses below the DLT and a dosage of 10 mg/d or 50 mg/wk is recommended for further development.
Journal ArticleDOI
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey Wallin,Johanna C. Bendell,Roel Funke,Mario Sznol,Konstanty Korski,Suzanne F. Jones,Genevive Hernandez,James W. Mier,Xian He,F. Stephen Hodi,Mitchell Denker,Vincent Leveque,Marta Cañamero,Galina Babitski,Hartmut Koeppen,James Ziai,Neeraj Sharma,Fabien Gaire,Daniel S. Chen,Daniel Waterkamp,Priti S. Hegde,David F. McDermott +21 more
TL;DR: Data suggest that the anti-VEGF and anti-PD-L1 combination improves antigen-specific T-cell migration, and trafficking lymphocyte increases are observed in tumors following bevacizumab and combination treatment.
Journal ArticleDOI
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
Anne O'Donnell,Sandrine Faivre,Howard A. Burris,Daniel Rea,Vassiliki A. Papadimitrakopoulou,N. Shand,Heidi Lane,Katharine Hazell,Ulrike Zoellner,John M. Kovarik,Cathryn Brock,Suzanne F. Jones,Eric Raymond,Ian Judson +13 more
TL;DR: Everolimus was satisfactorily tolerated at dosages up to 70 mg/wk and 10 mg/d with predictable PK and Antitumor activity and PD in tumors require further clinical investigation.